Ember Therapeutics, Inc., - Mariel Therapeutics, Inc.


Ember Therapeutics is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome.

Ember acquired over 450 patents and the rights to BMP-7 related research, and completed clinical trials and materials from Stryker Corporation.

Ember has assembled a management team and a scientific advisory board with extensive experience in the study of osteoarthritis, organ fibrosis, metabolic disease, therapeutic development, and BMP-7 technology


135 E. 57th St., 24th Floor
New York, New York 10022
United States

Get Directions

Upgrade Your Listing